The immune system in Duchenne muscular dystrophy: Friend or foe
暂无分享,去创建一个
J. Bluestone | A. Rosenberg | S. Villalta | Amy S Rosenberg | Jeffrey A Bluestone | S Armando Villalta | S Rosenberg | S. Armando Villalta | S. Rosenberg
[1] A. Sadeghi,et al. Redefinition of dystrophin isoform distribution in mouse tissue by RT-PCR implies role in nonmuscle manifestations of duchenne muscular dystrophy. , 1998, Molecular genetics and metabolism.
[2] E. Hoffman,et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. , 2009, The Journal of clinical investigation.
[3] I. Nonaka,et al. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): Immunocytochemical and genetic analyses , 1995, Muscle & nerve. Supplement.
[4] J. Tidball,et al. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice , 2001, The Journal of cell biology.
[5] Bernard Dan,et al. Pathophysiology of duchenne muscular dystrophy: current hypotheses. , 2007, Pediatric neurology.
[6] J. Kern,et al. The T‐cell receptor repertoire of regulatory T cells , 2008, Immunology.
[7] J. Sullivan,et al. Interleukin 35: A Key Mediator of Suppression and the Propagation of Infectious Tolerance , 2013, Front. Immunol..
[8] T. Partridge,et al. T-Cell-Dependent Fibrosis in the mdx Dystrophic Mouse , 2000, Laboratory Investigation.
[9] J. Mendell,et al. Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. , 2013, Human gene therapy.
[10] C. Reggiani,et al. Inflammation in muscular dystrophy and the beneficial effects of non‐steroidal anti‐inflammatory drugs , 2012, Muscle & nerve.
[11] R. Mantegazza,et al. Fibrosis and inflammation are greater in muscles of beta-sarcoglycan-null mouse than mdx mouse , 2014, Cell and Tissue Research.
[12] Mark M Davis,et al. Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. , 2013, Immunity.
[13] K. L. Gardner,et al. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. , 2007, The Journal of clinical investigation.
[14] J. Tidball,et al. Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. , 2001, Clinical immunology.
[15] Raffaele Iorio,et al. CD8+ T Cells in Facioscapulohumeral Muscular Dystrophy Patients with Inflammatory Features at Muscle MRI , 2011, Journal of Clinical Immunology.
[16] A. Manzur,et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. , 2004, The Cochrane database of systematic reviews.
[17] S. Batonnet-Pichon,et al. Srf-dependent paracrine signals produced by myofibers control satellite cell-mediated skeletal muscle hypertrophy. , 2012, Cell metabolism.
[18] M. Yano,et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. , 1996, The Journal of clinical investigation.
[19] H. Sweeney,et al. Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function , 2014, Neuromuscular Disorders.
[20] A. Pristerá,et al. Tumor Necrosis Factor‐α Inhibition of Skeletal Muscle Regeneration Is Mediated by a Caspase‐Dependent Stem Cell Response , 2008, Stem cells.
[21] S. Goerdt,et al. Differences in angiogenic potential of classically vs alternatively activated macrophages. , 1997, Immunobiology.
[22] Phoebe Lin,et al. The future of uveitis treatment. , 2014, Ophthalmology.
[23] J. Myśliwska,et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. , 2009, Clinical immunology.
[24] S. Gordon. Alternative activation of macrophages , 2003, Nature Reviews Immunology.
[25] J. Buckner,et al. IL-2 therapy in type 1 diabetes: "Trials" and tribulations. , 2013, Clinical immunology.
[26] J. Tidball,et al. Do immune cells promote the pathology of dystrophin-deficient myopathies? , 2001, Neuromuscular Disorders.
[27] J. Bluestone,et al. Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways , 2008, Immunological reviews.
[28] J. Tidball,et al. IFN-γ Promotes Muscle Damage in the mdx Mouse Model of Duchenne Muscular Dystrophy by Suppressing M2 Macrophage Activation and Inhibiting Muscle Cell Proliferation , 2011, The Journal of Immunology.
[29] J. Bluestone,et al. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy , 2014, Science Translational Medicine.
[30] K. Flanigan,et al. A Comparative Study of N-glycolylneuraminic Acid (Neu5Gc) and Cytotoxic T Cell (CT) Carbohydrate Expression in Normal and Dystrophin-Deficient Dog and Human Skeletal Muscle , 2014, PloS one.
[31] Yi-Wen Chen,et al. IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse , 2012, BMC Musculoskeletal Disorders.
[32] A. Musarò,et al. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice , 2002, The Journal of cell biology.
[33] J. Bluestone,et al. T Regulatory Cells in Autoimmune Diabetes: Past Challenges, Future Prospects , 2008, Journal of Clinical Immunology.
[34] M. Grounds,et al. Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment , 2008, Neuromuscular Disorders.
[35] H. Hartung,et al. Fingolimod is a potential novel therapy for multiple sclerosis , 2010, Nature Reviews Neurology.
[36] W. Młynarski,et al. Administration of CD4+CD25highCD127− Regulatory T Cells Preserves β-Cell Function in Type 1 Diabetes in Children , 2012, Diabetes Care.
[37] J. Ritz,et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.
[38] Abraham P. Fong,et al. DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. , 2012, Developmental cell.
[39] A. Engel,et al. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells , 1984, Annals of neurology.
[40] J. Tidball,et al. Shared signaling systems in myeloid cell-mediated muscle regeneration , 2014, Development.
[41] M. Grounds,et al. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFα function with Etanercept in mdx mice , 2006, Neuromuscular Disorders.
[42] C. Miao,et al. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[43] J. Tidball,et al. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. , 2011, Human molecular genetics.
[44] B. Paepe,et al. Cytokines and Chemokines as Regulators of Skeletal Muscle Inflammation: Presenting the Case of Duchenne Muscular Dystrophy , 2013 .
[45] B. De Paepe,et al. Cytokines and Chemokines as Regulators of Skeletal Muscle Inflammation: Presenting the Case of Duchenne Muscular Dystrophy , 2013, Mediators of inflammation.
[46] L. Tseng-Ong,et al. Eosinophilia of dystrophin-deficient muscle is promoted by perforin-mediated cytotoxicity by T cell effectors. , 2000, The American journal of pathology.
[47] M. Monden,et al. Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse. , 1995, Biochemical and biophysical research communications.
[48] H. Blau,et al. Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy. , 1994, Journal of immunology.
[49] T. Gotoh,et al. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. , 2008, Human molecular genetics.
[50] N. F. Kamel,et al. The effects of glucocorticoid therapy on the inflammatory and Dendritic cells in muscular dystrophies , 2006, International journal of experimental pathology.
[51] James J. Lee,et al. Major basic protein-1 promotes fibrosis of dystrophic muscle and attenuates the cellular immune response in muscular dystrophy. , 2008, Human molecular genetics.
[52] J. Mendell,et al. Dystrophin immunity in Duchenne's muscular dystrophy. , 2010, The New England journal of medicine.
[53] Y. Ohira,et al. Anti-interleukin-6 receptor antibody (MR16-1) promotes muscle regeneration via modulation of gene expressions in infiltrated macrophages. , 2014, Biochimica et biophysica acta.
[54] Mark M. Davis,et al. Deconstructing the Peptide-MHC Specificity of T Cell Recognition , 2014, Cell.
[55] G. Hansson,et al. Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. , 2013, The Journal of clinical investigation.
[56] L. Partridge,et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin , 2014, Nature Immunology.
[57] J. Bluestone,et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo , 2009, Nature Immunology.
[58] James M. Wilson. Autoimmunity, recessive diseases, and gene replacement therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[59] Andrew C. Chan,et al. Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.
[60] A. Manzur,et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. , 2008, The Cochrane database of systematic reviews.
[61] Qizhi Tang,et al. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation , 2008, Nature Immunology.
[62] L. Steinman. Four easy pieces : Interconnections between tissue injury, intermediary metabolism, autoimmunity, and chronic degeneration , 2006 .
[63] M. Krumbholz,et al. B cells and antibodies in multiple sclerosis pathogenesis and therapy , 2012, Nature Reviews Neurology.
[64] James J. Lee,et al. Prednisolone decreases cellular adhesion molecules required for inflammatory cell infiltration in dystrophin-deficient skeletal muscle , 2004, Neuromuscular Disorders.
[65] L. Skov,et al. Targeting of interleukin-17 in the treatment of psoriasis , 2014, Clinical, cosmetic and investigational dermatology.
[66] C. Benoist,et al. A Special Population of Regulatory T Cells Potentiates Muscle Repair , 2013, Cell.
[67] Yoshiya Tanaka,et al. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab , 2014, Annals of the rheumatic diseases.
[68] Yi-Ping Li,et al. TNF-α regulates myogenesis and muscle regeneration by activating p38 MAPK , 2007 .
[69] B. Pedersen,et al. Interleukin‐6 myokine signaling in skeletal muscle: a double‐edged sword? , 2013, The FEBS journal.
[70] Akinori Nakamura,et al. Evaluation of dystrophic dog pathology by fat‐suppressed T2‐weighted imaging , 2009, Muscle & nerve.
[71] K. Moore,et al. X chromosome-linked muscular dystrophy (mdx) in the mouse. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[72] G. D’Antona,et al. T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse , 2007, The Journal of pathology.
[73] J. Tidball,et al. Regulatory interactions between muscle and the immune system during muscle regeneration. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.
[74] P. Muñoz-Cánoves,et al. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. , 2008, Cell metabolism.